Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

0.3775 -0.0125 (-3.21%)
Streaming Delayed Price Updated: 2:45 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
Cue Biopharma Inc. (NASDAQ: CUE) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Where Cue Biopharma Stands With Analysts ↗
 
Via Benzinga
News headline image
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023 ↗
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
Via InvestorPlace
News headline image
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
The Truth About IPO Investing ↗
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying ↗
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks to Buy as Companies Ink Major Deals ↗
Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy. 
Via InvestorPlace
News headline image
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Host Investor Call
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks Sitting on Huge-Upside Catalysts ↗
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks. 
Via InvestorPlace
News headline image
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
News headline image
7 Hot Growth Stocks Poised to Triple in 2023 ↗
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher. 
Via InvestorPlace
News headline image
7 High-Potential Penny Stocks in the Biotech Sector ↗
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
News headline image
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
From Cue Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.